ArticleScientific reports2016
A potential panel of six-long non-coding RNA signature to improve survival prediction of diffuse large-B-cell lymphoma.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 67 citations in OpenAlex.
- An integrative network-based approach to identify driving gene communities in chronic obstructive pulmonary disease.NPJ systems biology and applications · 2024Article
- NEAT1 and CHROMR lncRNAs: a promising diagnostic tool for diffuse large B-cell lymphoma especially in elderly patients.Biomarkers in medicine · 2024Article
- LncRNA OR2A1-AS1 index predicts survival in germinal center-like diffuse large B-cell lymphoma.Journal of clinical laboratory analysis · 2022Article
- Long noncoding RNAs (lncRNAs) in human lymphomas.Genes & diseases · 2022Review
- Identification of a Two-lncRNA Signature with Prognostic and Diagnostic Value for Hepatocellular Carcinoma.Journal of oncology · 2022Article
- Development of a novel five-lncRNA prognostic signature for predicting overall survival in elderly patients with breast cancer.Journal of clinical laboratory analysis · 2022Article
- Competitive Endogenous RNA Network Involving miRNA and lncRNA in Non-Hodgkin Lymphoma: Current Advances and Clinical Perspectives.Biomedicines · 2021Review
- Review
- Comprehensive analyses of correlation and survival reveal informative lncRNA prognostic signatures in colon cancer.World journal of surgical oncology · 2021Article
- Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review.Experimental hematology & oncology · 2021Review
- Long Non-Coding RNAs in Diffuse Large B-Cell Lymphoma.Non-coding RNA · 2020Article
- Article
- Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine.Oncotarget · 2020Review
- Long noncoding RNA PVT1 promotes tumor growth and predicts poor prognosis in patients with diffuse large B-cell lymphoma.Cancer communications (London, England) · 2020Article
- lncRNAs-mRNAs Co-Expression Network Underlying Childhood B-Cell Acute Lymphoblastic Leukaemia: A Pilot Study.Cancers · 2020Article
- Non-Coding RNAs in Diffuse Large B-Cell Lymphoma.OncoTargets and therapy · 2020Review
- Crosstalk Between MYC and lncRNAs in Hematological Malignancies.Frontiers in oncology · 2020Review
- Long Noncoding RNAs in Diffuse Large B-Cell Lymphoma: Current Advances and Perspectives.OncoTargets and therapy · 2020Review
- Integrative analysis of miRNA and mRNA expression profiles reveals a novel mRNA/miRNA signature to improve risk classification for patients with gastric cancer.Oncology letters · 2019Article
- Development of a Reproducible Prognostic Gene Signature to Predict the Clinical Outcome in Patients with Diffuse Large B-Cell Lymphoma.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs (lncRNAs) represent an emerging layer of cancer biology and have been implicated in the development and progression of cancers. However, the prognostic significance of lncRNAs in diffuse large-B-cell lymphoma (DLBCL) remains unclear and needs to be systematically investigated. In this study, we obtained and analyzed lncRNA expression profiles in three cohorts of 1043 DLBCL patients by repurposing the publicly available microarray datasets from the Gene Expression Omnibus (GEO) database. In the discovery series of 207 patients, we identified a set of six lncRNAs that was significantly associated with patients' overall survival (OS) using univariate Cox regression analysis. The six prognostic lncRNAs were combined to form an expression-based six-lncRNA signature which classified patients of the discovery series into the high-risk group and low-risk group with significantly different survival outcome (HR = 2.31, 95% CI = 1.8 to 2.965, p < 0.001). The six-lncRNA signature was further confirmed in the internal testing series and two additional independent datasets with different array platform. Moreover, the prognostic value of the six-lncRNA signature is independent of conventional clinical factors. Functional analysis suggested that six-lncRNA signature may be involved with DLBCL through exerting their regulatory roles in known cancer-related pathways, immune system and signaling molecules interaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.